Mercurna is a Dutch biotechnology start-up that develops novel therapeutics based on a highly innovative messenger RNA (mRNA)-based platform. This platform combines sequence engineered mRNA with lipid nanoparticles and peptide based homing with the goal of achieving highly localized protein expression.
Chronic kidney disease
Novel formulations derived from this platform are particularly suited for (chronic) inflammatory diseases as it leaves non target organs and locations unaffected, preventing the side effects associated with contemporary immuno suppressive medication. To prove the value of these new and targeted therapeutics, Mercurna is initially focussing on the development of mCura1 as a candidate treatment for inflammation in the kidney mCura1 is suitable for various types of chronic kidney disease.
Expanding our targets
Success in chronic kidney disease paves the way for application of our technology platform in other chronic inflammatory diseases and ultimately in other organs.